The global NGS sample preparation market is projected to reach USD 2.7 billion by 2024 from USD 1.1 billion in 2018, at a CAGR of 18.7% during the forecast period. Factors such as advancements in NGS platforms, reduced cost of sequencing, and improving reimbursement scenario for NGS-based diagnostic tests are driving the growth of this market.
This study is used four major activities to estimate the current market size for the NGS sample preparation market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Download PDF Brochure@ NGS Sample Preparation Market
The reagents, and consumables segment to dominate the overall NGS sample preparation market in 2018
Based on product, the NGS sample preparation market is segmented into workstations and reagents & consumables. The reagents & consumables segment was further subsegmented into library preparation, target enrichment, and quality control, on the basis of workflow.
In 2018, the reagents and consumables segment accounted for the largest share of the NGS sample preparation market. Factors such as the decreasing cost of sequencing; availability of cost-efficient and advanced NGS platforms; increasing applications of NGS in different fields such as drug and biomarker discovery, diagnostics, agro-genomics, and animal research; increasing research activity involving sequencing; and the availability of research grants (that are driving the adoption of NGS) have all contributed to the growth of this market.
The diagnostics segment is estimated to grow at the highest CAGR during the forecast period
Based on application, the NGS sample preparation market is segmented into diagnostics, drug discovery, agricultural & animal research, and other applications. The diagnostics segment is estimated to grow at the highest rate during the study period owing to the growing number of new cancer cases across the globe, favorable reimbursement scenario for NGS-based tests in the US, and increasing focus of key market players on developing NGS-based products & services for cancer and NIPT.
North America dominated the NGS sample preparation market in 2018
Geographically, the NGS sample preparation market is segmented into North America (US and Canada), Europe (Germany, France, the UK, and the Rest of Europe), Asia Pacific (China, Japan, India, and the Rest of Asia Pacific), and the Rest of the World (RoW). North America accounted for the largest share of the overall NGS sample preparation market in 2018 followed by Europe.
The large share of North America can be attributed to the favorable initiatives by government and private bodies for the development and adoption of NGS technologies, wide adoption of NGS diagnostics in the region, increasing number of NGS-based research & clinical applications in the region, growing research on cancer, rising awareness of NGS services, and the presence of leading NGS service providers, in the region.
Some of the prominent players in the NGS sample preparation market include Illumina Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), Beckman Coulter (a subsidiary of Danaher), and Becton, Dickinson and Company (BD) (US) among others.
Request Sample Pages@ NGS Sample Preparation Market
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.